Biopower Operations Corp

2023 Q2 Form 10-K Financial Statement

#000149315223021562 Filed on June 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q4 2022

Balance Sheet

Concept 2023 Q2 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $830.00 $830.00
YoY Change -100.0% -99.14% -99.14%
Cash & Equivalents $825.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $12.89K $12.89K $12.89K
Prepaid Expenses
Receivables $331.00 $331.00 $330.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.22K $14.05K $14.05K
YoY Change -97.84% -85.36% -85.36%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00 -$1.00 $0.00
YoY Change 33.33% -133.33%
TOTAL ASSETS
Total Short-Term Assets $13.22K $14.05K $14.05K
Total Long-Term Assets $4.00 -$1.00 $0.00
Total Assets $13.22K $14.05K $14.05K
YoY Change -97.84% -85.36% -85.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.576M $2.747M $2.747M
YoY Change 50.65% 31.15% 31.15%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.625M $2.570M $2.570M
YoY Change -23.09% -24.7% -24.7%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.889M $5.954M $5.954M
YoY Change 19.06% 8.11% 8.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.889M $5.954M $5.954M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $6.889M $5.954M $5.954M
YoY Change 19.06% 8.11% 8.11%
SHAREHOLDERS EQUITY
Retained Earnings -$15.74M -$10.35M
YoY Change 64.45% 8.29%
Common Stock $4.588K $4.564K
YoY Change 0.53% 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.876M -$5.940M -$5.940M
YoY Change
Total Liabilities & Shareholders Equity $13.22K $14.05K $14.05K
YoY Change -97.84% -85.36% -85.36%

Cashflow Statement

Concept 2023 Q2 2022 Q4 2022

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001510832
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
usd
CY2021Q4 BOPO Convertible Debt Variable Priced Conversion Current
ConvertibleDebtVariablePricedConversionCurrent
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
usd
CY2021 BOPO Loan Costs
LoanCosts
usd
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
CY2021 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Stock Issued1
StockIssued1
usd
CY2022 BOPO Noncash Common Stock Issued For Accrued Severance
NoncashCommonStockIssuedForAccruedSeverance
usd
CY2022 BOPO Noncash Common Stock Issued For Accrued Salary Related Party
NoncashCommonStockIssuedForAccruedSalaryRelatedParty
usd
CY2021 BOPO Debt Discount
DebtDiscount
usd
CY2021 BOPO Initial Derivative
InitialDerivative
usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-11-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
333-172139
CY2022 dei Entity Registrant Name
EntityRegistrantName
BioPower Operations Corporation
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4460232
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
20801 Biscayne Blvd.
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 403
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
CY2022 dei City Area Code
CityAreaCode
(786)
CY2022 dei Local Phone Number
LocalPhoneNumber
923-0272
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
7362910 usd
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45625000 shares
CY2022 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2022 dei Auditor Firm
AuditorFirmId
5041
CY2022 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
825 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95973 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
12893 usd
CY2022Q4 us-gaap Assets
Assets
14049 usd
CY2021Q4 us-gaap Assets
Assets
95973 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
375000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
66583 usd
CY2022Q4 BOPO Convertible Debt Variable Priced Conversion Current
ConvertibleDebtVariablePricedConversionCurrent
157167 usd
CY2022Q4 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2021Q4 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1320700 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1320700 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
262050 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5953792 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5507151 usd
CY2022Q4 BOPO Common Stock Owed Value
CommonStockOwedValue
125000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4564 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4501 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4279317 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4140411 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10349524 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9556990 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14049 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95973 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
571700 usd
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
175000 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1163484 usd
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
461263 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
1163484 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
461263 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-591784 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-286263 usd
CY2022 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
69722 usd
CY2022 BOPO Loan Costs
LoanCosts
3750 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-200750 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-155061 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-792534 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-441324 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45302198 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43915714 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-792534 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-441324 usd
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2500 usd
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
154167 usd
CY2022 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
69722 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
331 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12893 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12879 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
195266 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
639545 usd
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
39531 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
375000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
306111 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-204027 usd
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
223750 usd
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
374991 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
300000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-401259 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-95148 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
95973 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95973 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
825 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95973 usd
CY2021 us-gaap Stock Issued1
StockIssued1
1000000 usd
CY2021 BOPO Noncash Common Stock Issued For Accrued Severance
NoncashCommonStockIssuedForAccruedSeverance
37500 usd
CY2021 BOPO Noncash Common Stock Issued For Accrued Salary Related Party
NoncashCommonStockIssuedForAccruedSalaryRelatedParty
54615 usd
CY2022 BOPO Debt Discount
DebtDiscount
220750 usd
CY2022 BOPO Initial Derivative
InitialDerivative
-220750 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4364469 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
300000 usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000000 usd
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2500 usd
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
37500 usd
CY2021 BOPO Stock Issued During Period Value Common Stock Issued For Accrued Salary Related Party
StockIssuedDuringPeriodValueCommonStockIssuedForAccruedSalaryRelatedParty
54615 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-441324 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
CY2022 BOPO Stock Issued During Period Value Sale Of Common Stock
StockIssuedDuringPeriodValueSaleOfCommonStock
374991 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-111022 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-792534 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-792534 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10349524 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_z34eQkb4IX8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_863_zCwBiidmUZoh">Concentration</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Six customers, including two related parties, account for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211201__20221130__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--SixCustomersMember_zKMKb51COV8c" title="Concentration risk, percentage">100</span>% of sales during the year ended November 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zIGFP15E0Vy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_867_z3i8F6D9KlY4">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2022Q4 us-gaap Inventory Net
InventoryNet
12893 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5357 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
95973 usd
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Notes Payable
NotesPayable
694198 usd
CY2015Q3 us-gaap Notes Payable
NotesPayable
113031 usd
CY2015Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-12-31
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
320089 usd
CY2021Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
275071 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
568912 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
484156 usd
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 BOPO Cash Placement Fee Rate
CashPlacementFeeRate
0.04 pure
CY2023Q2 BOPO Management Advisory Fee
ManagementAdvisoryFee
0.015 pure

Files In Submission

Name View Source Status
0001493152-23-021562-index-headers.html Edgar Link pending
0001493152-23-021562-index.html Edgar Link pending
0001493152-23-021562.txt Edgar Link pending
0001493152-23-021562-xbrl.zip Edgar Link pending
bopo-20221130.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bopo-20221130_def.xml Edgar Link unprocessable
bopo-20221130_cal.xml Edgar Link unprocessable
bopo-20221130_pre.xml Edgar Link unprocessable
bopo-20221130_lab.xml Edgar Link unprocessable
from10-k.htm Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
from10-k_htm.xml Edgar Link completed